LNCaP nuclear extract (Testosterone treated)
Active Motif's LNCaP nuclear extract (Testosterone treated) was prepared from cell cultures of the human prostate adenocarcinoma LNCaP cell line. The LNCaP cell line was originally derived from a supraclavicular lymph node metastatic lesion of a 50 year old Caucasian patient with metastatic prostate carcinoma. Prostate cancer is the second most common neoplasia in men. Because it is a hormone-responsive cancer, its treatment at initial stages of development typically involves anti-androgen adjuvant therapy. The fibroblast-like LNCaP cell line retains malignant properties that are characteristic of human prostate adenocarcinoma, including resistance to interferon, the expression of high levels of acid phosphatase, androgen receptors and Prostate Specific Antigen (PSA), and hormone responsiveness. Treatment of LNCaP cells with testosterone and its biologically active metabolite dihydrotestosterone (DHT) stimulates cell growth and acid phosphatase production. The LNCaP cell line is most commonly used in research as a model for human prostate cancer.